Low plasma pyridoxal 5′-phosphate concentration and MTHFR 677C → T genotypes are associated with increased risk of hypertension

International Journal for Vitamin and Nutrition Research

Volumn 78, Issue 1, 2008, Pages 33-40

  Lin, Ping Ting ^a   Cheng, Chien Hsiang ^a   Wei, James Cheng Chung ^a   Huang, Yi Chia ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Folate; Homocysteine; Hypertension; Methylenetetrahydrofolate reductase; Pyridoxal 5 phosphate

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; HOMOCYSTEINE; PYRIDOXAL 5 PHOSPHATE; VITAMIN B GROUP;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; FOLIC ACID BLOOD LEVEL; GENE MUTATION; GENOTYPE; HUMAN; HYPERTENSION; MALE; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL;

ALLELES; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; HYDROLASES; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PYRIDOXAL PHOSPHATE; RISK FACTORS;

EID: 48749115959     PISSN: 03009831     EISSN: None     Source Type: Journal    
DOI: 10.1024/0300-9831.78.1.33     Document Type: Article

References (54)

1. Heux, S., Morin, F., Lea, R.A., Ovcaric, M., Tajouri, L. and Griffiths, L.R. (2004) The methylenetetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens. Res. 27, 663-667.
2. Dominiczak, A.F. and Bohr, D. (1990) Cell membrane abnormalities and the regulation of intracellular calcium concentration in hypertension. Clin. Sci. 79, 415-423.
3. 6 deficiency-induced hypertension. J. Hypertens. 11, 1357-1362.
4. 6 on the systolic blood pressure of rats in various animal models of hypertension. J. Hypertens. 14, 355-363.
5. Vasdev, S., Ford, C. A., Parai, S., Longerich, L. and Gadag, V. (1999) Dietary vitamin B6 supplementation attenuates hypertension in spontaneously hypertensive rats. Mol. Cell. Biochem. 200, 155-162.
6. Aybak, M., Sermet, A., Ayyildiz, M. O. and Karakilcik, A.Z. (1995) Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Drug. Res. 45, 1271-1273.
7. Starkebaum, G. and Harlan, J. M. (1986) Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J. Clin. Invest. 77, 1370-1376.
8. Kottke-Marchant, K., Green, R., Jacobsen, D. and Discorte-to, P. (1990) Subcytotoxic homocysteine increases monocyte adhesion to human aortic endothelial cells. Blood 76, 511-517.
9. Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattstrom, L.E., Ueland, P.M., Palma-Reis, R.J., Boers, G.H., Sheahan, R.G., Israelsson, B., Uiterwaal, C.S., Me-leady, R., McMaster, D., Verhoef, P., Witteman, J., Rubba, P., Bellet, H., Wautrecht, J.C., de Valk, H.W., Sales, init?, Luis, A.C., Parrot-Rouland, F.M., Tan, K.S., Higgins, I., Garcon, D., Andria, G. et al. (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277, 1775-1781.
10. Malinow, M.R., Levenson, J., Giral, P., Nieto, F.J., Raza-vian, M., Segond, P. and Simon, A. (1995) Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 114, 175-183.
11. Sutton-Tyrrell, K., Bostom, A., Selhub, J. and Zeigler-Johnson, C. (1997) High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96, 1745-1749.
12. Mendis, S., Athauda, S.B., Naser, M. and Takahashi, K. (1999) Association between hyperhomocy steinemia and hypertension in Sri Lankans. J. Int. Med. Res. 27, 38-44.
13. Lip, G. Y., Edmunds, E., Hee, F.L., Blann, A.D. and Beevers, D.G. (2001) A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am. J. Hypertens. 14, 823-828.
14. Fakhrzadeh, H., Ghotbi, S., Pourebrahim, R., Heshmat, R., Nouri, M., Shafaee, A. and Larijani, B. (2005) Plasma homocysteine concentration and blood pressure in healthy Iranian adults: the Tehran Homocysteine Survey (2003-2004). J. Hum. Hypertens. 19, 869-876.
15. Engbersen, A.M., Franken, D.G., Boers, G.H., Stevens, E.M., Trijbels, F.J. and Blom, H.J. (1995) Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet. 56, 142-150.
16. Kang, S.S., Zhou, J., Wong, P.W., Kowalisyn, J. and Strokosch, G. (1998) Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 43, 414-421.
17. Wilcken, D.E.L., Wang, X.L., Sim, A.S. and McCredie, R.M. (1996) Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C sub 677T mutation. Arterioscler. Thromb. Vasc. Biol. 16, 878-882.
18. Inamoto, N., Katsuya, T., Kokubo,Y., Mannami,T., Asai,T., Baba, S., Ogata, J., Tomoike, H. and Ogihara, T. (2003) Association of methylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis depending on smoking status in a Japanese general population. Stroke 34, 1628-1633.
19. Williams, C., Kingwell, B. A., Burke, K., McPherson, J. and Dart, A. M. (2005) Folic acid supplementation for 3 weeks reduces pulse pressure and large artery stiffness independent of MTHFR genotype. Am. J. Clin. Nutr. 82, 26-31.
20. Nakata, Y., Katsuya, T., Takami, S., Sato, N., Fu, Y., Ishikawa, K., Takiuchi, S., Rakugi, H., Miki, T., Higaki, J. and Ogihara, T. (1998) Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am. J. Hypertens. 11, 1019-1023.
21. Araki, A. and Sako,Y. (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 422, 43-52.
22. Bates, C. J., Pentieva, K.D., Matthews, N. and Macdonald, A. (1999) A simple, sensitive and reproducible assay for pyridoxal 5'-phosphate and 4-pyridoxic acid in human plasma. Chin. Chim. Acta. 280, 101-111.
23. Dominici, R., Luraschi, P. and Franzini, C. (2004) Measurement of C-reactive protein: two high sensitivity methods compared. J. Clin. Lab. Anal. 18, 280-284.
24. Anderson, J.L., King, G.J., Thomson, J., Todd, M., Bair, T. L., Muhlestein, J. B. and Carlquist, J. F (1997) A mutation in the methylenetetrahydrofolate reductase gene is not associated with increase risk for coronary artery disease or myocardial infarction. J. Am. Coll. Cardiol. 30, 1206-1211.
25. Markus, H. S., Ali, N., Swaminathan, R., Sankaralingam, A., Molloy, J. and Powell, J. (1997) A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 28, 1739-1743.
26. Malinow, M.R., Bostom, A.G., and Krauss, R.M. (1999) Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99, 178-182.
27. nd ed., p. 269, West Publishing Press, New York.
28. 6: a status report. J. Nutr. 120, 1503-1507.
29. 12, Pantothenic acid, Biotin, and Choline. National Academy Press, Washington, D.C.
30. McCully, K.S. (1996) Homocysteine and vascular disease. Nat. Med. 2, 386-389.
31. 12, and folate. Am. J. Epidemiol. 143, 845-859.
32. Lee, B. J., Lin, P. T., Liaw, Y.P., Chang, S. J., Cheng, C.H. and Huang, Y. C. (2003) Homocysteine and risk of coronary artery disease: Folate is the important determinant of plasma homocysteine concentration. Nutr. 19, 577-583.
33. Mujumdar, VS., Aru, G.M. and Tyagi, S.C. (2001) Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J. Cell. Biochem. 82, 491-500.
34. Rolland, P.H., Friggi, A., Barlatier, A., Piquet, P., Latrille, V., Faye, M.M., Gujllou, J., Charpioy, P., Bodard, H., Ghininghelli, O., Calaf, R., Luccioni, R. and Garcon, D. (1995) Hyperhomocysteinemia-induced vascular damage in the minipig. Circulation 91, 1161-1174.
35. Matthias, D., Becker, C.H., Riezler, R. and Kindling, P.H. (1996) Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and SHR following application of high doses of methionine. Atherosclerosis 122, 201-216.
36. Osganian, S. K., Stampfer, M. J., Spiegelman, D., Rimm, E., Cutler, J. A., Feldman, H. A., Montgomery, D.H., Webber, L.S., Lytle, L.A., Bausserman, L. and Nader, P.R. (1999) Distribution of and factors associated with serum homocysteine levels in children: Child and Adolescent Trial for Cardiovascular Health. JAMA 281, 1189-1196.
37. Neugebauer, S., Tarnow, L., Stehouwer, C., Teerlink, T., Baba, T., Watanabe, T. and Parving, H. H. (2002) Total plasma homocysteine is associated with hypertension in Type I diabetic patients. Diabetologia 45, 1315-1324.
38. Kahleova, R., Palyzova, D., Zvara, K., Zvarova, J., Hrach, K., Novakova, I., Hyanek, J., Bendlova, B. and Kozich, V. (2002) Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am. J. Hypertens. 15, 857-864.
39. Lim, U. and Cassano, P. A. (2002) Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Epidemiol. 156, 1105-1113.
40. Nygard, O., Vollset, S.E., Refsum, H., Stensvold, I.,Tverdal, A., Nordrehaug, J.E., Ueland, M. and Kvale, G. (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274, 1526-1533.
41. Perry, I.J. (1999) Homocysteine and risk of stroke. J. Cardiovasc. Risk. 6, 235-240.
42. 6, pyridoxal phosphate, and folate. Am. J. Cardiol. 75, 1107-1111.
43. Zhan, S., Gao, Y., Yin, X., Huang, Y., Hu, Y and Li, L. (2000) A case-control study on the relationship between abnormal homocysteine metabolism and essential hypertension. Zhonghua Liu Xing Bing Xue Za Zhi (Chinese Journal of Epidemiology) 21, 194-197.
44. Virdis, A., Ghiadoni, L., Salvetti, G., Versari, D., Taddei, S. and Salvett, A. (2002) Hyperhomocyst(e)inemia: is this a novel risk factor in hypertension? J. Nephrol. 15, 414-421.
45. Sundstrom, J., Sullivan, L., D'Agostino, R. B., Jacques, P. F., Selhub, J., Rosenberg, I.H., Wilson, P.W., Levy, D. and Vasan, R. S. (2003) Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension 42, 1100-1105.
46. Forman, J. P., Rimm, E. B., Stampfer, M. J. and Curhan, G. C. (2005) Folate intake and the risk of incident hypertension among US women. JAMA 293, 320-329.
47. Paulose, C.S., Dakshinamurti, K., Packer, S. and Stephens, N.L. (1986) Hypertension in pyridoxine deficiency. J. Hypertens. 4, S174-S175.
48. Paulose, C.S., Dakshinamurti, K., Packer, S. and Stephens, N.L. (1988) Sympathetic stimulation and hypertension in the pyridoxine-deficient adult rat. Hypertens. 11, 387-391.
49. Brophy, M.H. (1990) Zinc, preeclampsia, and gamma-aminobutyric acid. Am. J. Obstet. Gynecol. 163, 242-243.
50. 6 levels in healthy middle-aged adults. Ann. N.Y. Acad. Sci. 585, 499-501.
51. 6. J. Hypertens. 13, 327-332.
52. Mayer, E.L., Jacobsen, D. W. and Robinson, K. (1996) Homocysteine and coronary atherosclerosis. J. Am. Coll. Cardiol. 27, 517-527.
53. Kang, S.S., Wong, P.W.K., Cook, H.Y., Norusis, M. and Messer, J. V. (1986) Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J. Clin. Invest. 77, 1482-1486.
54. Jacobsen, D.W., Gatautis, V.J., Green, R., Robinson, K., Savon, S.R., Secic, M., Ji, J., Otto, J.M. and Taylor, L.M. Jr. (1994) Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin. Chem. 40, 873-881.